Background International guidelines recommend that an average individual time in therapeutic range should be >65-70% for optimal efficacy and safety outcomes whilst on a vitamin K antagonists (VKA). The SAMe-TT 2 R 2 score would help decision making by identifying those newly diagnosed atrial fibrillation patients that could do well on vitamin K antagonists.
Objective
To validate the predictive value of the SAMe-TT 2 R 2 score for discriminating those who would achieve a high time in therapeutic range(≥65%) in a prospective 'real world' cohort of atrial fibrillation patients initiating oral anticoagulation therapy with VKA.
Methods
We studied an inception cohort of consecutive non-valvular atrial fibrillation patients that initiated oral anticoagulation in our outpatient anticoagulation clinic. Baseline SAMe-TT 2 R 2 score was calculated. At 6 months, we calculated time in therapeutic range using the Rosendaal method.
Results
We included 459 patients: 222 (47%) male, median age 76 (interquartile range70-82); Median CHA 2 DS 2 -VASc score was 4 (3-5) and medianHAS-BLED score was 3 (2) (3) . Median SAME-TT 2 R 2 score was 2 (1-2).
At 6 months, the mean ± standard deviationtime in therapeutic range at was 64±17% overall, and 248 (54%) patients had a time in therapeutic range value >65%. Patients with a SAME-TT 2 R 2 score 0-1 had a mean time in therapeutic range of 67±18% whereas in patients with a SAME-TT 2 R 2 score ≥2, mean time in therapeutic range was 61±16%, p<0.001. The odds ratio (OR) for having a low time in therapeutic range value was 2.10 (95%CI 1.44-3.06, p<0.001) for those patients with a SAME-TT 2 R 2 score ≥2.
Conclusions
In a prospective 'real world' inception cohort of atrial fibrillation patients initiating oral anticoagulation with acenocoumarol, we have validated the clinical value of the SAME-TT 2 R 2 score, for the identification of patients who would have poor quality anticoagulation. Thus, rather than imposing a 'trial of vitamin K antagonists' for such patients (and exposing such patients to thromboembolic risks), we can a priori identify those patients who can (not cannot) do well on a vitamin K antagonists. Such patients In 2013, Apostolakis et al. 10 those with SAMe-TT 2 R 2 score<2).
We have recently validated this score in a retrospective analysis of our "real world" anticoagulated atrial fibrillation patients 11 . Also, a high SAMe-TT 2 R 2 score (reflecting poor anticoagulation control with poor time in therapeutic range) was associated with more bleeding, adverse cardiovascular events and mortality during follow-up. Prior validation studies [11] [12] [13] have been made on retrospective analysis of clinic or hospital cohort studies, and thus, the objective of the present study was to validate a priori the use of the SAMe-TT 2 R 2 score in a contemporary inception cohort of anticoagulation-
naïve atrial fibrillation patients who were prospectively initiating oral anticoagulation with a vitamin K antagonist, acenocoumarol.
METHODS
We included consecutive non-valvular atrial fibrillation patients that initiating oral anticoagulation with acenocoumarolin our out-patient anticoagulation clinic, between January and December 2013, who maintained oral anticoagulation and were followed up prospectively for 6 months, for this study. This inception cohort of patients was 15 .
At baseline SAMe-TT 2 R 2 score was calculated as previously described 10 . At six months we calculated time in therapeutic range using the established Rosendaal method 16 .
Once the patient reached steady dose, the frequency of INR testing was once a month, so all patients had a minimum of 8 visits.
Exclusion criteria
Patients with valvular atrial fibrillation (prosthetic or not) were excluded. We also excluded those patients that did not receive at least 6 months oral anticoagulation treatment, those suffered from any event leading to temporarily discontinue oral anticoagulation, as this would influence achievement of stable anticoagulation.
Statistical analysis Median SAMe-TT 2 R 2 score was 2 (IQR 1-2) and 55% patients had a score <2. Only 18 patients had a score >3. Overall the mean time in therapeutic range at six months was 64±17%, and 248 patients (54%) had a time in therapeutic range value >65%.
After a follow-up of 6 months, patients with a SAMe-TT 2 R 2 score <2 had a mean time in therapeutic range value of 67±18% compared to a mean time in therapeutic range of 61±16% amongst patients SAMe-TT 2 R 2 score ≥2 [p=0.001]. The odds ratio (OR) for having a low time in therapeutic range for patients with a SAMe-TT 2 R 2 score ≥2 was 2.10 (95%CI 1.44-3.06, p<0.001).
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9
There was no relationship between time in therapeutic range values at 6 months and thrombotic risk based on a CHA 2 DS 2 -VASc categorisation of <2 and ≥2, with mean TTRs of 64±17% vs 67±17%, respectively (p=0.232). For the HAS-BLED score, patients with a score <3 had a mean time in therapeutic range of 66±17% vs patients with HAS-BLED ≥3, who had a mean time in therapeutic range value of 63±17% (p=0.08).
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

DISCUSSION
In this study, we validated for the first time the value of SAMe-TT 2 R 2 score in a large consecutive "real world" inception cohort of patients who were initiating oral anticoagulation. As our patients were on acenocoumarol, or paper gives an additional use of the SAMe-TT 2 R 2 score for this VKA drug, which is the second most commonly used coumarin (after warfarin) in the world.Based on our analysis, patients with a high SAMe-TT 2 R 2 score (≥2) would have a 2 fold increased risk for suboptimal quality of oral anticoagulation, as assessed by a low time in therapeutic range value at 6 months after initiating treatment with a vitamin K antagonist.
Despite the NOACs 17 being increasingly used, the VKAsremain the main oral anticoagulation used in many countries, especially where economic considerations are a factor. One criterion often used to sanction NOAC use is a time in therapeutic range value at 6 months <65% 9, 17 . Thus, many patients have to undergo a 'trial of vitamin K antagonist' (or 'warfarin stress test') to show that high time in therapeutic range cannot be achieved, before a NOAC is allowed.
Thus, use of a simple score based on clinical risk factors allows the clinician to make an informed decision whether a non-anticoagulated atrial fibrillation patient is likely (or not) to do well on a vitamin K antagonist. This is relevant since average time in therapeutic range may be poor or suboptimal in inception cohorts for as long as 6 months (being an average of 47% in one recent US study) 18 , and this may translate into worse thromboembolic outcomes in this inception phase, being increased by 70% 19 .
Those patients with a high SAMe-TT 2 R 2 can be justifiably started on a NOAC up front (without a 'warfarin stress test') or be targeted for additional interventions (eg. more intense education, regular review and follow-up, etc 20 ) whilst those patients with a SAMe-TT 2 R 2 score <2 can be started on a vitamin K antagonist, as they are likely to do well. Such an approach is illustrated in Figure 2 .
The efficacy and safety of therapy is closely associated to the quality of oral anticoagulation management 6, 11 . These patients are best managed in specialized anticoagulation clinics, which achieves higher values of time in therapeutic range and provides the best outcomes 6, [18] [19] [20] [21] [22] . Even in clinical trials, patients in centres with high
average time in therapeutic range may have less profound differences in efficacy outcomes between NOACs and warfarin 23 . The maintenance dose of VKA is influenced by many different factors, including race, dietary vitamin K intake, comorbidities (eg. liver disease and acute illness) or whether the patient may be taking interacting drugs 24 . The average individual time in therapeutic range generally increases over time, but even in very well and experienced patients, their time in therapeutic range value can decrease during follow-up 11 . This is especially important in patients who initiate conventional oral anticoagulation more INR fluctuations occur during the first 3 months 24 . In our cohort, for example, we found that the average time in therapeutic range value at 6 months was 64% and only 49% had a time in therapeutic range value up to 65%.
It is important to note that our study was performed using acenocoumarol as vitamin K antagonist drug. Compared to warfarin, acenocoumarol has a shorter half life, about 8 hours 25 . Hence, patients taking acenocoumarol may be more likely to have unstable anticoagulation control than those taking warfarin 26 . In addition, acenocoumarol has been related with a higher risk for bleeding than warfarin 22 . Thus, use of the SAMe-TT 2 R 2 score in this population taking acenocoumarol as their drug may confer additional advantages.
Prediction algorithms (including clinical and genetic data) for VKA treatment could also be another option 27 . However the use of these algorithms in clinical practice remains uncertain, given the contradictory results of two controlled trials of genotype-guided dosing [28] [29] [30] . In contrast to complex (and expensive) genotyping, we have now prospectively validated the use of an easy, simple and cheap score that would detect which atrial fibrillation patients are likely to do well on vitamin K antagonists(with good average time in therapeutic range).This is important since even small differences in time in therapeutic range could translate to lower risk of adverse events whilst on VKA 5 .
Limitations
We only included in those patients that continued treatment during the initial 6 months, so some very high risk patients that suffer from acute events during the first months may have been excluded. Given our small sample size and followup duration,
we would have been underpowered to examine thromboembolic and bleeding events in this cohort. Also, the proportion of patients with a very high SAMe-TT 2 R 2 score (>3) was low. All patients included were Caucasian, who were managed in a dedicated anticoagulation clinic, where the average overall time in therapeutic range was reasonably good, at 64% time in therapeutic range.
We made reference to NICE guidelines criteria for defining good time in therapeutic range (≥65%) as this was based following a comprehensive evidence synthesis and appraisal, as well as cost effectiveness 9 . They also considered poor anticoagulation control as defined by 2 INR values higher than 5 or 1 INR value higher than 8 within the past 6 months, 2 INR values less than 1.5 within the past 6 months or time in therapeutic range less than 65%; however, we did not perform these additional measures within our cohort.
Finally, another limitation is the possibility that low time in therapeutic range could be due to low adherence to treatment, which would also affect the further treatment with NOACs if they would be used. However, patients regularly attended the anticoagulation clinic and were reviewed by nurses if INR was out of range.
Conclusion
In a prospective 'real world' inception cohort of anticoagulation-naïve patients initiating oral anticoagulation with acenocoumarol, we have validated the clinical value of the SAMe-TT 2 R 2 score, for the identification of which patients would have poor quality anticoagulation. These patients would benefit from additional strategies for improving anticoagulation control with VKA or alternative oral anticoagulant drugs. • In a prospective 'real world' inception cohort of AF patients initiating oral anticoagulation with acenocoumarol, we have validated the clinical value of the SAME-TT 2 R 2 score, for the identification of patients who would have poor quality anticoagulation.
• We can identify those patients who can (not cannot) do well on a VKA. Such patients would benefit from additional strategies for improving anticoagulation control with VKA or alternative oral anticoagulant drugs.
